Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases
AssigneeKymab Limited
InventorsMartina RAUNER, Lorenz C. HOFBAUER, Uwe PLATZBECKER, Ulrike BASCHANT
Life of this patent
Estimating the term…
Abstract
The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.
Claims15
A method of treating a primary or secondary sclerosing disease in a subject, comprising administering to the subject a protein comprising an amino acid sequence that has at least 70% identity with the sequence of SEQ ID NO:
- 1, or a fragment thereof.
(canceled)
(canceled)
A method of diagnosing a disease associated with increased Bone Morphogenetic Protein (BMP) receptor activation in a subject, comprising detecting a member of the TGF-β/BMP family using a protein comprising an amino acid sequence that has at least 70% identity with the sequence of SEQ ID NO:
- 1 in a subject.
(canceled)
A method of diagnosing a primary or secondary sclerosing disease in a subject, comprising detecting a member of the TGF-β/BMP family using a protein comprising an amino acid sequence that has at least 70% identity with the sequence of SEQ ID NO:
- 1 in a subject.
Dependencies are inferred from the claim text.